Biomedical Engineering Reference
In-Depth Information
polymeric matrix and porous biodegradable
reservoir devices for slow-release drug delivery.
Ophthalmic Surg Lasers 27(5):384-391
11. Thombre AG, Himmelstein KJ (1984) Model-
ling of drug release kinetics from a laminated
device having an erodible drug reservoir. Bio-
materials 5(5):250-254
12. Richards Grayson AC, Cima MJ, Langer R
(2004) Molecular release from a polymeric
microreservoir device: Influence of chemistry,
polymer swelling, and loading on device per-
formance. J Biomed Mater Res A 69
(3):502-512. doi:
10.1002/jbm.a.30019
13. Kawashima Y, Yamamoto H, Takeuchi H,
Hino T, Niwa T (1998) Properties of a peptide
containing
DL
-lactide/glycolide copolymer
nanospheres prepared by novel emulsion sol-
vent diffusion methods. Eur J Pharm Biopharm
45(1):41-48. doi:
10.1016/S0939-6411(97)
00121-5
14. Gopferich A (1996) Mechanisms of polymer
degradation and erosion. Biomaterials 17
(2):103-114
15. Siepmann J, Elkharraz K, Siepmann F, Klose D
(2005) How autocatalysis accelerates drug
release from PLGA-based microparticles: a
quantitative treatment. Biomacromolecules 6
(4):2312-2319. doi:
10.1021/bm050228k
16. Kompella UB, Bandi N, Ayalasomayajula SP
(2003) Subconjunctival nano- and microparti-
cles sustain retinal delivery of budesonide, a
corticosteroid capable of inhibiting VEGF
expression. Invest Ophthalmol Vis Sci 44
(3):1192-1201
17. Kadam RS, Tyagi P, Edelhauser HF, Kompella
UB (2012) Influence of choroidal neovascular-
ization and biodegradable polymeric particle
size on transscleral sustained delivery of triam-
cinolone acetonide. Int J Pharm 434
(1-2):140-147. doi:
10.1016/j.ijpharm.2012.
05.025
18. Yang H, Tyagi P, Kadam RS, Holden CA,
Kompella UB (2012) Hybrid dendrimer
hydrogel/PLGA nanoparticle platform sus-
tains drug delivery for one week and antiglau-
coma effects for four days following one-time
topical
intraceptor nanoparticle therapy reduces
angiogenesis and fibrosis in primate and
murine macular degeneration. ACS Nano 7
(4):3264-3275. doi:
10.1021/nn305958y
20. Cho YK, Uehara H, Young JR, Tyagi P, Kom-
pella UB, Zhang X, Luo L, Singh N, Archer B,
Ambati BK (2012) Flt23k nanoparticles offer
additive benefit in graft survival and anti-
angiogenic effects when combined with triam-
cinolone. Invest Ophthalmol Vis Sci 53
(4):2328-2336. doi:
10.1167/iovs.11-8393
21. Panyam J, Dali MM, Sahoo SK, Ma W, Chak-
ravarthi SS, Amidon GL, Levy RJ, Labhasetwar
V (2003) Polymer degradation and in vitro
release of a model protein from poly(
D
,
L
-lac-
tide-co-glycolide) nano- and microparticles.
J Control Release 92(1-2):173-187
22. Amrite AC, Kompella UB (2006) Nanoparti-
cles for ocular drug delivery. In: Gupta RB,
Kompella UB (eds) Nanoparticle technology
for drug delivery, vol 159. Taylor and Francis
Group, New York, pp 319-360
23. Shmueli RB, Bhise NS, Green JJ (2013) Evalu-
ation of polymeric gene delivery nanoparticles
by nanoparticle tracking analysis and high-
throughput flow cytometry. J Vis Exp (73):
e50176. doi:
10.3791/50176
24. Wright M (2012) Nanoparticle tracking analy-
sis for the multiparameter characterization and
counting of nanoparticle suspensions. Meth-
ods Mol Biol 906:511-524. doi:
10.1007/
978-1-61779-953-2_41
25. Zolls S, Tantipolphan R, Wiggenhorn M, Win-
ter G, Jiskoot W, Friess W, Hawe A (2012)
Particles in therapeutic protein formulations,
Part 1: overview of analytical methods. J
Pharm Sci 101(3):914-935. doi:
10.1002/jps.
23001
26. den Engelsman J, Garidel P, Smulders R, Koll
H, Smith B, Bassarab S, Seidl A, Hainzl O,
Jiskoot W (2011) Strategies for the assessment
of protein aggregates in pharmaceutical bio-
tech product development. Pharm Res 28
(4):920-933.
doi:
10.1007/s11095-010-
0297-1
27. Shelke NB, Kadam R, Tyagi P, Rao VR, Kom-
pella UB (2011) Intravitreal poly(
L
-lactide)
microparticles sustain retinal and choroidal
delivery of TG-0054, a hydrophilic drug
intended for neovascular diseases. Drug Deliv
Transl Res 1(1):76-90. doi:
10.1007/s13346-
010-0009-8
28. ICH Q1A (R2) (2003) Guidance (Interna-
tional Conference on Harmonisation). Stability
testing of new drug substances and products
administration.
ACS Nano
6
(9):7595-7606. doi:
10.1021/nn301873v
19. Luo L, Zhang X, Hirano Y, Tyagi P, Barabas P,
Uehara H, Miya TR, Singh N, Archer B, Qazi
Y, Jackman K, Das SK, Olsen T, Chennama-
neni SR, Stagg BC, Ahmed F, Emerson L,
Zygmunt K, Whitaker R, Mamalis C, Huang
W, Gao G, Srinivas SP, Krizaj D, Baffi J, Ambati
J, Kompella UB, Ambati BK (2013) Targeted
